scroll to top
0

EBSCO Auth Banner

Let's find your institution. Click here.

Advanced Search Results For "MIFEPRISTONE"

1 - 10 of 10,442 results for
 "MIFEPRISTONE"
Results per page:

The efficacy of mifepristone combined with methotrexate for the treatment of ectopic pregnancy: a systematic review and meta-analysis.

Publication Type: Report

Source(s): Annals of medicine [Ann Med] 2022 Dec; Vol. 54 (1), pp. 3269-3285.

Authors:

Abstract: Objective: Systematically evaluate the clinical efficacy of mifepristone combined with methotrexate therapy for ectopic pregnancy (EP), analyze the experimental designs, put forward improvement ideas.Methods: RCTs of mifepristone combined with mifepris...

View details

Mifepristone versus balloon catheter for labor induction: a cohort study.

Publication Type: Academic Journal

Source(s): The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians [J Matern Fetal Neonatal Med] 2022 Dec; Vol. 35 (25), pp. 9331-9335. Date of Electronic Publication: 2022 Jan 27.

Abstract: Objective: to compare trans-cervical balloon catheter with oral administration of mifepristone for induction of labor.Methods: Retrospective cohort study including a total of 325 patients; labor was induced with Foley catheter (group I, n  = 220) or mi...

View details

Non-genomic uterorelaxant actions of corticosteroid hormones in rats: An in vitro and in vivo study.

Publication Type: Academic Journal

Source(s): European journal of pharmacology [Eur J Pharmacol] 2022 Nov 15; Vol. 935, pp. 175346. Date of Electronic Publication: 2022 Oct 21.

Abstract: Aims: We aimed to identify the short-term effects of a glucocorticoid (GC) and a mineralocorticoid (MC) on non-pregnant and late pregnant rat uterine contractions to estimate their tocolytic potential.Methods: The in vitro contractility studies were pe...

View details

Determination of Mifepristone (RU-486) and Its Metabolites in Maternal Blood Sample after Pharmacological Abortion.

Publication Type: Academic Journal

Source(s): Molecules (Basel, Switzerland) [Molecules] 2022 Nov 06; Vol. 27 (21). Date of Electronic Publication: 2022 Nov 06.

Abstract: The aim of the study was the development and validation of the UHPLC-QqQ-MS/MS method for the determination of mifepristone in human blood as well as the identification and quantification of its metabolites after self-induced pharmacological abortion. ...

View details

Mifepristone combined with ethacridine lactate for third-trimester stillbirth induction: a 5-year experience from Shanghai.

Publication Type: Academic Journal

Source(s): BMC pregnancy and childbirth [BMC Pregnancy Childbirth] 2022 Oct 26; Vol. 22 (1), pp. 790. Date of Electronic Publication: 2022 Oct 26.

Authors:

Abstract: Objective: To review and analyze the efficacy and safety of mifepristone combined with ethacridine lactate for induction of stillbirth in the third trimester.Methods: All patients with stillbirth in late pregnancy (≥ 28 weeks) in a university-affiliate...

View details

Yikang decoction facilitates embryo implantation in mice with implantation dysfunction via upregulation of LIF expression.

Publication Type: Academic Journal

Source(s): Transplant immunology [Transpl Immunol] 2022 Dec; Vol. 75, pp. 101662. Date of Electronic Publication: 2022 Jul 08.

Abstract: Objective: The present study investigates the effects and mechanisms of Yikang decoction on embryo implantation in mice.Methods: Totally, mature female mice were randomly divided into four groups: normal, implantation failure (mifepristone treatment), ...

View details

[Mifepristone: from pre- to post-protection].

Publication Type: Academic Journal

Source(s): Nederlands tijdschrift voor geneeskunde [Ned Tijdschr Geneeskd] 2022 Oct 20; Vol. 166. Date of Electronic Publication: 2022 Oct 20.

Abstract: All current hormonal contraceptives have side effects and contraindications related to estrogens and progestins. Users are often dissatisfied with this. There is a great need for a new contraceptive drug without these hormones with the associated side ...

View details

The effects of mifepristone on the structure of human decidua and chorion and Bax and Bcl-2 expression at early stage of pregnancy.

Publication Type: Academic Journal

Source(s): BMC pharmacology & toxicology [BMC Pharmacol Toxicol] 2022 Jul 23; Vol. 23 (1), pp. 55. Date of Electronic Publication: 2022 Jul 23.

Authors:

Abstract: Background: As a progesterone receptor antagonist, mifepristone combined with misoprostol is widely used to terminate early pregnancy in clinical practice. It has also been reported that mifepristone may cause cell death in decidual cells and result in...

View details

Barriers to abortion provision in primary care in New England, 2019-2020: A qualitative study.

Publication Type: Academic Journal

Source(s): Contraception [Contraception] 2023 Jan; Vol. 117, pp. 39-44. Date of Electronic Publication: 2022 Aug 12.

Abstract: Objective: To assess barriers to and facilitators of abortion provision among abortion-trained primary care providers.Study Design: We conducted 21 qualitative in-depth interviews with 20 abortion-trained family physicians and one internal medicine phy...

View details

Mifepristone (RU-486 ® ) as a Schedule IV Controlled Drug-Implications for a Misleading Drug Policy on Women's Health Care.

Publication Type: Academic Journal

Source(s): International journal of environmental research and public health [Int J Environ Res Public Health] 2022 Jul 08; Vol. 19 (14). Date of Electronic Publication: 2022 Jul 08.

Abstract: Background: Mifepristone (RU-486) has been approved for abortion in Taiwan since 2000. Mifepristone was the first non-addictive medicine to be classified as a schedule IV controlled drug. As a case of the "misuse" of "misuse of drugs laws," the policy ...

View details
sponsored